EGFR and neoplasm: From a meta-analysis published in 2017 covering all first line studies, a significant predictive benefit was demonstrated for chemotherapy plus EGFR antibody therapy in patients with left-sided tumours (HR 0.75 [95% CI 0.67-0.84] and 0.78 [95% CI 0.70-0.87] for OS and PFS, respectively) (66–68).